Fulgent Genetics to announce Q2 2026 results on July 30

0 min read     Updated on 10 Jul 2026, 04:18 AM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Fulgent Genetics will announce its Q2 2026 financial results on July 30, 2026, followed by a conference call at 4:30 PM ET. The company operates in laboratory services and therapeutic development, targeting precision medicine integration.

powered bylight_fuzz_icon
45182873

*this image is generated using AI for illustrative purposes only.

Fulgent Genetics, Inc. will release its second quarter 2026 financial results after the market closes on Thursday, July 30, 2026. The company, which operates a laboratory services business and a therapeutic development business, scheduled the announcement to provide updates on its performance. Management will host a conference call the same day at 4:30 PM ET to discuss the results and answer questions from the investment community.

Conference Call Details

The conference call will be accessible through a live audio webcast on the Investor Relations section of Fulgent Genetics' website. An audio replay of the call will be available at the same location following the event.

Key Event Information

Event Date & Time
Q2 2026 Financial Results Release July 30, 2026 (after market close)
Conference Call July 30, 2026 at 4:30 PM ET
Webcast Access http://ir.fulgentgenetics.com

Fulgent Genetics provides technical laboratory and testing services, including professional interpretation of results by licensed physicians. Its therapeutic development business focuses on drug candidates for treating cancers using a nanoencapsulation and targeted therapy platform. The company aims to transition into a fully integrated precision medicine company.

How will the performance of the nanoencapsulation and targeted therapy platform impact the company's transition to a fully integrated precision medicine model?

What market trends in laboratory services and therapeutic development could influence Fulgent Genetics' financial results in the second half of 2026?

Will the conference call reveal any strategic partnerships or acquisitions to accelerate the company's precision medicine goals?

like15
dislike
Must Read Next

Corporate Actions

Prism Johnson Acquires Additional 8.5% Stake in Samini Ceramics for ₹15.31 Crore, Total Holding Rises to 98.5% 4 hrs ago
ZEE Entertainment Shareholders Greenlight Warrant Issuance to Promoter Group on Preferential Terms 4 hrs ago
ABB India Declares Special Dividend of ₹90 Per Share 7 hrs ago
no imag found

Stocks

IndiGo to Launch Mumbai-Amsterdam Flights Using Airbus A321XLR from October 25, 2026 4 hrs ago
LG Balakrishnan & Bros Signs Land Development Deal With Brigade Enterprises in Mysore 4 hrs ago